Company Overview
Pasithea Therapeutics Corp. operates as a clinical-stage biotechnology entity dedicated to the discovery, research, and development of therapeutic solutions for central nervous system disorders, RASopathies, and various forms of cancer. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry where innovation in drug development and clinical trials defines operational focus. As of the latest data, the company maintains a market capitalization of $17.09 million while employing a workforce of just four individuals. This minimal employee count relative to the biotechnology sector's typical scale suggests a lean operational structure, likely relying on strategic partnerships or outsourced manufacturing for its lead product candidate, PAS-004. The market cap figure of $17.09 million places the company in the micro-cap category, indicating it is a highly speculative investment often driven by potential future clinical milestones rather than current operational profitability. The absence of reported annual revenue further contextualizes its position as a pre-commercial entity where value is derived from intellectual property and pipeline advancement rather than sales volume.
Financial Health
The company reports a net income of $-13,494,476 and an EBITDA of $-13,194,081 over the trailing twelve-month period, with revenue figures listed as N/A. The significant gap between the reported net income and EBITDA reveals a cost structure heavily influenced by non-operating expenses, such as interest or other financial charges, which depress net income more severely than operating earnings. Free cash flow stands at $-7,940,062, indicating that the company is consuming cash reserves to fund its research and development activities rather than generating liquidity from operations. This negative cash flow trajectory reflects the high burn rate typical of clinical-stage biotechnology firms but necessitates careful monitoring of cash runway to ensure solvency. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial sales necessary to generate positive margins or scale economies. The company holds cash of $4.12 million while reporting N/A for total debt, resulting in a debt-to-equity ratio of N/A. This lack of debt suggests a conservative balance sheet approach where the firm prioritizes preserving capital over leveraging equity to finance operations. The current ratio is 4.01, which indicates strong short-term liquidity relative to immediate obligations, providing a substantial buffer against potential cash burn. Return on Equity is -89.9% and Return on Assets is -53.7%, metrics that reveal the company is currently destroying value per unit of equity and assets due to its stage of development and lack of revenue generation.
Valuation Assessment
The trailing P/E ratio is N/A, while the forward P/E is -1.09, a discrepancy that implies earnings are currently negative and any forward estimate relies on projected profitability that has not yet materialized in the financial statements. The price-to-book ratio is 0.45, suggesting the market values the company's equity at less than half its book value, which often occurs with distressed or unprofitable firms where assets may not be fully utilized for revenue generation. The price-to-sales ratio is N/A and the EV/EBITDA is -0.10, indicating that traditional valuation multiples based on sales or earnings are not applicable without current profitability or sales volume. These alternative valuation metrics highlight the difficulty in applying standard industry benchmarks to a clinical-stage entity that has not yet crossed into commercialization. The stock has traded between a 52-week low of $0.28 and a 52-week high of $3.79, creating a wide trading range that reflects significant price volatility common in small-cap biotechnology stocks. The beta value is 0.20, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it moves independently of general market trends.
Growth & Income
Revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A, meaning there is no historical data to compare current performance against prior periods. Since the company reports N/A for revenue and negative earnings, it is impossible to determine if earnings are growing faster or slower than revenue, as the business has not yet generated positive financial returns. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, the company reinvests its limited resources entirely into research, development, and clinical trials rather than returning capital to investors. This reinvestment strategy is standard for clinical-stage biotechnology companies but results in a growth and income profile characterized by zero current income and reliance on future clinical success for value appreciation.